$-1.41
(Market cap
$29,535 Mln
Revenue (TTM)
$9,857 Mln
P/E Ratio
21.5
P/B Ratio
1.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.1 %
-
ROCE
5.3 %
-
Industry P/E
33.27
-
EV/EBITDA
11.8
-
Debt to Equity
0.3
-
Book Value
$--
-
EPS
$9.3
-
Face value
--
-
Shares outstanding
147,637,117
10 Years Aggregate
CFO
$39,799.12 Mln
EBITDA
$51,067.67 Mln
Net Profit
$32,807.58 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Biogen (BIIB)
| 12.9 | 3.8 | 9.4 | 52.0 | -12.8 | -13.3 | -1.9 |
|
BSE Sensex*
| -9.5 | 1.8 | 2.8 | -5.5 | 6.8 | 7.7 | 11.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Biogen (BIIB)
| 15.1 | -40.7 | -6.6 | 15.4 | -2.0 | -17.5 | -1.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Biogen (BIIB)
|
198.6 | 29,534.8 | 9,857.4 | 1,372.4 | 18.4 | 7.4 | 21.5 | 1.6 |
| 350.5 | 191,704.4 | 37,238.0 | 7,800.0 | 31.7 | 82.9 | 24.7 | 20.9 | |
| 56.2 | 116,663.5 | 48,482.0 | 7,275.0 | 21.6 | 37.7 | 16 | 5.8 | |
| 226.4 | 52,427.0 | 250,549.0 | 1,559.0 | 0.9 | -- | 34.1 | 16.1 | |
| 124.3 | 155,928.8 | 29,734.0 | 9,216.0 | 39.5 | 40.9 | 17.1 | 6.6 | |
| 779.8 | 94,623.4 | 403,430.0 | 4,762.0 | 1.6 | -246.4 | 20.5 | 5.0 | |
| 114.9 | 298,256.0 | 65,593.0 | 8,935.0 | 24.7 | 18.3 | 34 | 6.4 | |
| 151.6 | 293,693.5 | 56,053.0 | 13,533.8 | 30.3 | 32.7 | 22.1 | 7.6 | |
| 26.0 | 149,154.5 | 63,315.0 | 7,491.0 | 16.7 | 8.1 | 20 | 1.6 | |
| 80.0 | 33,358.0 | 9,509.0 | 2,643.0 | 37.3 | 61.2 | 13 | 10.3 |
Shareholding Pattern
View DetailsAbout Biogen (BIIB)
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for... spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. Read more
-
President, CEO & Director
Mr. Christopher A. Viehbacher
-
President, CEO & Director
Mr. Christopher A. Viehbacher
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Biogen (BIIB)
What is the current share price of Biogen Inc (BIIB) Today?
The share price of Biogen Inc (BIIB) is $198.64 (NASDAQ) as of 15-Jun-2026 16:00 EDT. Biogen Inc (BIIB) has given a return of -12.84% in the last 3 years.
What is the current PB & PE ratio of Biogen Inc (BIIB)?
The P/E ratio of Biogen Inc (BIIB) is 21.51 times as on 12-Jun-2026, a 35 discount to its peers’ median range of 33.27 times.
The P/B ratio of Biogen Inc (BIIB) is 1.58 times as on 12-Jun-2026, a 73 discount to its peers’ median range of 5.79 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
19.96
|
1.41
|
|
2024
|
13.69
|
1.34
|
|
2023
|
32.47
|
2.55
|
|
2022
|
13.20
|
3.00
|
|
2021
|
22.74
|
3.25
|
What is the 52 Week High and Low of Biogen Inc (BIIB)?
The 52-week high and low of Biogen Inc (BIIB) are Rs 205.97 and Rs 121.06 as of 16-Jun-2026.
What is the market cap of Biogen Inc (BIIB)?
Biogen Inc (BIIB) has a market capitalisation of $ 29,535 Mln as on 12-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Biogen Inc (BIIB)?
Before investing in Biogen Inc (BIIB), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.